Schizophrenia
Conditions
Interventions
None listed
Sponsors
Janssen Pharmaceutical K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following A to D (Confirm the eligibility of subjects at the time of registration.) A. Patients who have been continuously treated with paliperidone palmitate sustained-release suspension for injection in an intramuscular fashion for 4 weeks (Hereinafter referred to as "Paliperidone 4-Week Subcutaneous Intramuscular Injection") without concomitant use of other antipsychotics for at least 4 months in patients with schizophrenia, and in whom the safety and tolerability were confirmed. B. Patients who switched to this drug 4 weeks after the last dose of paliperidone 4 weeks after the last dose of paliperidone. C. Paliperidone at the same dose in at least the last 2 4-week IM injections prior to switching. D. Patients who understand the contents of this investigation and agree to participate in the investigation (Informed Consent)
Exclusion criteria
Exclusion criteria: Patients not meeting Key inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events related to QT prolongation (Includes relevant laboratory tests.), Concomitant use of oral antipsychotics, etc., Adherence (Treatment Compliance) | — |
Countries
Japan
Contacts
Public ContactKeiko Kawamura
Janssen Pharma Medical Affairs Delivery Unit
Outcome results
None listed